Lito Sousa's Wife Says He's Already Received Experimental Medicine
8 Articles
8 Articles
Understand how Creutzfeldt-Jakob, the influencer's disease Lito Sousa Lito Sousa will begin testing the substance for a test treatment against Creutzfeldt-Jakob. The influencer will be the first person in the world to test the product, which can open doors on the findings for the disease, still unhealed. The substance is the ALN-6457 from the pharmaceutical company Regeneron in the United States. There is not much published about it because it h…
The condition of Creutzfeldt-Jakob can cause dementia, brain changes, tremors and loss of motor skills The post Lito Sousa receives experimental medication for rare neurodegenerative disease; family says it is still early to know if there will be improvement apareceu primeiro em ND More
The influencer Lito Sousa received the experimental medication authorized for the treatment of Creutzfeldt-Jakob disease (DCJ) and did not present any drug-related complications, according to Mila Seidl, Lito's wife. In the video, Mila said that it is not possible to determine, at this time, whether the medication could interrupt or slow the progression of the disease or produce any [...] The post VIDEO: Lito Sousa woman says that he has already…
In a video published on the influencer's channel, Mila stated that it is not yet possible to know what the effect of the medicine will be
In a video published on the networks, Mila stated that it is not yet possible to know what the effect of the medicine will be
Lito Sousa's wife, Mila Seidl, updated on Monday (14) the health status of the influencer, who received an experimental substance for Creutzfeldt-Jakob's disease. According to her, Lito had no complications caused by the treatment and remains stable in the ICU, where he has been hospitalized since last Tuesday (8) for complications of the disease itself. Read more (09/14/2026
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
